Vector BioMed Selected as Top Lentiviral Vector Design and Manufacturing Company
Life Sciences Review recognizes the pure-play lentiviral vector company’s work to help Asia-Pacific healthcare providers manufacture CAR-T therapies closer to patients.
GAITHERSBURG, Md., Nov. 9, 2026 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced that it has been named Lentiviral Vector Design and Manufacturing Company of the Year in Asia 2026 by Life Sciences Review. The recognition highlights the company’s specialized lentiviral vector expertise and its work helping healthcare providers around the world develop and deliver advanced cell and gene therapies closer to where patients live. [Read more…]
16 CAR-T Therapies and Counting:
How the CAR-T Market Is Evolving and The Companies Leading the Charge
Since 2017, an incredible 16 CAR-T cell therapies have reached commercialization, with several more nearing the finish line. Seven therapies have been approved by the U.S. FDA, after which approvals for them were issued in other major markets as well. These include:
- Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lisocabtagene maraleucel)
- Abecma (idecabtagene vicleucel)
- Carvykti (ciltacabtagene autoleucel)
- Aucatzyl (obecabtagene autoleucel)
Beyond the U.S., six CAR-T therapies (Carteyva, Yikaida, Yorwida, Zevor-cel, Fucaso, and Satri-cel) have been approved by China’s National Medical Products Administration (NMPA), including Satri-cel, which made history this year as the world’s first CAR-T cell therapy approved for a solid tumor. [Read more…]
New Frontiers in Gene-Editing and Stem Cell Innovation – Interview with Dr. Chen-Tsai of Applied StemCell
In this interview with Dr. Ruby Yanru Chen-Tsai, Chief Scientific Officer and Co-founder of Applied StemCell Inc. (ASC), we explore the company’s groundbreaking work at the intersection of gene-editing technologies and stem cell innovation. Based in Milpitas, California, ASC offers an optimized portfolio of tools for basic research, drug discovery, bioprocessing, bioproduction, and preclinical applications.
In this interview, we dive into Dr. Yanru Chen-Tsai’s background, ASC’s unique product portfolio, its TARGATT™ gene editing technology, and the company’s future trajectory. [Read more…]
Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control
In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.
The pace never slows when your mission is to enable lifesaving science! [Read more…]
- 1
- 2
- 3
- …
- 14
- Next Page »




